D.C.’s Vanda Pharmaceuticals Inc. has locked in a deal with a West Coast biotech to commercialize a drug for a rare skin ...

Wedbush analyst David Nierengarten maintained a Buy rating on AnaptysBio (ANAB – Research Report) today and set a price target of $40.00. The ...

AnaptysBio, Inc. ( NASDAQ:ANAB ) shareholders should be happy to see the share price up 13% in the last month. But ...

Fintel reports that on February 4, 2025, Wolfe Research initiated coverage of AnaptysBio (NasdaqGS:ANAB) with a Outperform ...

Jennison Associates LLC boosted its holdings in shares of AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) by 1.6% in the fourth quarter, according to the company in its most recent 13F filing with the ...

Analysts have recently evaluated AnaptysBio and provided 12-month price targets. The average target is $36.17, accompanied by ...

Vanda and AnaptysBio have announced an exclusive worldwide licence agreement to develop and commercialise imsidolimab to ...

AnaptysBio (NASDAQ:ANAB – Get Free Report)‘s stock had its “neutral” rating reissued by analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They currently have a $19.00 ...

Wolfe Research analyst Andy Chen initiated coverage of AnaptysBio (ANAB) with an Outperform rating and $25 price target The stock’s current ...

Vanda expects to immediately begin preparing BLA and MAA applications for the U.S. and EU.

AnaptysBio (NASDAQ:ANAB) stock maintained its Neutral rating and $19.00 price target from H.C. Wainwright. Currently trading ...

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) and AnaptysBio, Inc. (Anaptys) (Nasdaq: ANAB) today announced an exclusive, ...